Does suppressing luteinising hormone secretion reduce the miscarriage rate? Results of a randomised controlled trial
- 15 June 1996
- Vol. 312 (7045) , 1508-1511
- https://doi.org/10.1136/bmj.312.7045.1508
Abstract
Objective: To determine whether prepregnancy pituitary suppression of luteinising hormone secretion with a luteinising hormone releasing hormone analogue improves the outcome of pregnancy in ovulatory women with a history of recurrent miscarriage, polycystic ovaries, and hypersecretion of luteinising hormone. Design: Randomised controlled trial. Setting: Specialist recurrent miscarriage clinic. Subjects: 106 women with a history of three or more consecutive first trimester miscarriages, polycystic ovaries, and hypersecretion of luteinising hormone. Interventions: Women were randomised before conception to receive pituitary suppression with a luteinising hormone releasing hormone analogue followed by low dose ovulation induction and luteal phase progesterone (group 1) or were allowed to ovulate spontaneously and then given luteal phase progesterone alone or luteal phase placebo alone (group 2). No drugs were prescribed in pregnancy. Main outcome measures: Conception and live birth rates over six cycles. Results: Conception rates in the pituitary suppression and luteal phase support groups were 80% (40/50 women) and 82% (46/56) respectively (NS). Live birth rates were 65% (26/40) and 76% (35/46) respectively (NS). In the luteal phase support group there was no difference in the outcome of pregnancy between women given progesterone and those given placebo pessaries. Live birth rates from an intention to treat analysis were 52% (26/50 pregnancies) in the group given pituitary suppression and 63% (35/56) in the controls (NS). Conclusions: Prepregnancy suppression of high luteinising hormone concentrations in ovulatory women with recurrent miscarriage and hypersecretion of luteinising hormone does not improve the outcome of pregnancy. The outcome of pregnancy without pituitary suppression is excellent. Hypersecretion of luteinising hormone seems not to be causally related to early pregnancy loss Further research should be directed at other endocrine factors controlling implantation Excellent live birth rates can be achieved with supportive care alone in a specialised clinicKeywords
This publication has 23 references indexed in Scilit:
- Identification of nitric oxide synthase in human uterusHuman Reproduction, 1995
- Polycystic ovaries and levels of gonadotrophins and androgens in recurrent miscarriage: prospective study in 50 womenBJOG: An International Journal of Obstetrics and Gynaecology, 1993
- Recurrent Miscarriage ‐ Outcome After Supportive Care in Early PregnancyAustralian and New Zealand Journal of Obstetrics and Gynaecology, 1991
- Hypersecretion of luteinising hormone, infertility, and miscarriageThe Lancet, 1990
- Influence of past reproductive performance on risk of spontaneous abortion.BMJ, 1989
- Recurrent early miscarriage and polycystic ovaries.BMJ, 1988
- Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome.BMJ, 1988
- Improvement of in vitro fertilisation after treatment with buserelin, an agonist of luteinising hormone releasing hormoneBMJ, 1988
- Reduced in‐vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phaseBJOG: An International Journal of Obstetrics and Gynaecology, 1985
- INDUCTION OF OVULATION FOR IN-VITRO FERTILISATION USING BUSERELIN AND GONADOTROPINSThe Lancet, 1984